Login to Your Account



Super ‘bowel’ score: Furiex riding high after phase III victory with eluxadoline

By Randy Osborne
Staff Writer

Tuesday, February 4, 2014

Furiex Pharmaceuticals Inc.’s Phase III win with lead compound eluxadoline in diarrhea-predominant irritable bowel syndrome (IBS-D) turned investors’ eyes to next moves, including a potential partner for the locally acting mu opioid receptor agonist and delta opioid receptor antagonist or a possible buyout.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription